<DOC>
	<DOCNO>NCT02834663</DOCNO>
	<brief_summary>Title study : Effects Ranibizumab delay regression non-proliferative diabetic retinopathy ( NPDR ) DME assess microaneurysm change : A pilot study Objectives To evaluate effect intravitreal Ranibizumab injection microvascular change eye mild-to-moderate NPDR DME Primary objective : To compare microvascular change assess microaneurysm count eye mild-to-moderate NPDR DME intravitreal Ranibizumab injection baseline 6 month treatment . Secondary objective : To investigate efficacy endpoint include microvascular , anatomical , visual acuity change safety mild-to-moderate NPDR DME intravitreal Ranibizumab injection baseline 6 month treatment .</brief_summary>
	<brief_title>Effects Ranibizumab Delay Regression Non-proliferative Diabetic Retinopathy ( NPDR ) With DME Assessed Microaneurysm Changes : A Pilot Study</brief_title>
	<detailed_description>Title study : Effects Ranibizumab delay regression non-proliferative diabetic retinopathy ( NPDR ) DME assess microaneurysm change : A pilot study Study Rationale : Diabetic retinopathy lead disease cause acquire vision loss 20 make diabetic macular edema neovascularization . In recent young generation , prevalence type 2 diabetes grow , burden sight-threatening retinopathy increase trend.1 Pathologically , angiogenesis main cause destroy structure eye induces visual function disorder VEGF playing important role increase migration proliferation endothelial cell increase permeability blood vessels.2,3 VEGF make endothelial cell retinal tissue , perivascular cell , pigment endothelial cell hypoxia . And hypoxic condition intraocular tissue key regulator intra ocular angiogenesis VEGF , balance VEGF angiogenesis inhibitor determine neovascular proliferation diabetic retinopathy.4 VEGF also induce expression cell-to-cell contact molecule ( intracellular adhesion molecule-1 , ICM-1 ) adhesion leukocytes help inflammatory response5 , mediator destroys blood retinal barrier , affect protein tight junction , make microaneurysm increase permeability capillary , make liquid leakage macular edema.5,6 Microanuerysm early clinical manifestation , saccular local lesion perivascular cell protrude damage area capillary wall . According Stitt AW et al9 , diabetic microaneurysm non-functioning extrusion vascular system deep part inner retinal capillary plexus . It sometimes disappear blocked blood clot , hand , new microanerysm occur vascular bed structure . Through change , investigator know course diabetic retinopathy know generation rate microaneurysm associate clinically significant progression macular edema ( CSME ) mild-to-moderate nonproliferative diabetic retinopathy .10,11 In addition , number microanerysm important prognostic indicator estimate progression regression diabetic retinopathy , predict whether become good worse diabetic retinopathy.12 Kohner Sleightholm13 describe concept first time 1986 , association number microvascular flow severity diabetic retinopathy . In recent year report measure number microaneurysm turnover rate associate appearance disappearance microaneurysm , predictor progression diabetic retinopathy macular edema.14 To delay progression diabetic retinopathy improve macular edema , laser photocoagulation important role.15 Although laser photocoagulation treatment effect diabetic retinopathy reduce amount VEGF micraneurysm degenerate neovascularization laser therapy , problem many limitation - peripheral visual field defect , night blindness , progression macular edema etc. , disease cure good time limit laser therapy due cataract , vitreous hemorrhage turbidity . As alternative method solve limitation , anti-VEGF therapy.6 According previous study result , intraocular injection Bevacizumab inhibit occur neovascularization block VEGF receptor .17 Recently , several study report injected intravitreal anti-VEGF , macular edema improve neovascularization inhibit , reduce leakage neovascularization.3 Especially , Leicht SF et al18 report number microaneurysms turnover rate NPDR ( non-proliferative diabetic retinopathy ) patient inject Ranibizumab . And result show entire number microaneurysms turnover rate decrease , could mean regression diabetic retinopathy could decide therapeutic effect . On study , fluorescein fundus angiography , average number microaneurysms significantly decrease intravitreal injection anti-VEGF therapy ( p &lt; 0.05 ) . The decrease 35.70±24.79 % treatment group statistically high 13.95±38.21 % control group fellow eye ( p &lt; 0.05 ) . The result find decreased concentration intravitreal VEGF inhibit progression diabetic retinopathy , endothelial cell proliferation endothelial cell damage retinal capillary perivascular cell . Sjølie AK et al12 report up-regulation VEGF occur microaneurysms cause endothelial cell proliferation inflammation effusion reaction , anti-VEGF effective early diabetic retinopathy . But less effectiveness late diabetic retinopathy reach non-changing point . Also Kohner EM et al19 report diabetic retinopathy lesion reversible could delay early diabetic retinopathy . So far , change microaneurysms late diabetic retinopathy uncertain , would find accord anti-VEGF therapy , investigator could get clue surrogate marker represent treatment result diabetic retinopathy . This study design find clinical evaluation reduction rate fluorescein angiography microaneurysm examination tool research NPDR DME treatment result assess microaneurysm count , timely monitor anti-VEGF therapy . Objectives To evaluate effect intravitreal Ranibizumab injection microvascular change eye mild-to-moderate NPDR DME Primary objective : To compare microvascular change assess microaneurysm count eye mild-to-moderate NPDR DME intravitreal Ranibizumab injection baseline 6 month treatment . Secondary objective : To investigate efficacy endpoint include microvascular , anatomical , visual acuity change safety mild-to-moderate NPDR DME intravitreal Ranibizumab injection baseline 6 month treatment . Primary secondary endpoint : Primary endpoint : To compare microaneurysmal change intravitreal Ranibizumab injection baseline 6 month treatment . ) Microaneurysm count FAG ( mm² ) 1,2 3 field ETDRS ( Fundus Photograph ) ) ii ) Microaneurysm turnover rate FAG ( mm² ) - 1 ) microaneurysm formation rate index = ( number new microaneurysms detect 6 month follow Up/number microaneurysms baseline ) * 100 2 ) microaneurysm disappearance rate index = = ( number new microaneurysms disappear 6 month follow Up/number microaneurysms baseline ) * 100 3 ) microaneurysm count change index = ( number microaneurysms 6 months/number microaneurysms baseline ) * 100 Secondary endpoint : To compare microvascular , anatomical , visual acuity change safety intravitreal Ranibizumab injection baseline 6 month treatment . ) Other microvascular change - 1,2 3 field ETDRS ( Fundus Photograph ) - Non-perfusion area FAG ( mm² ) periphery - Cotton wool spot &amp; hard exudation count fundus photo &amp; OCT ( mm² ) ii ) The change CMT - Circle Diameters : 1 mm ETDRS spectralis OCT ; Heidelberg Engineering iii ) The change best correct visual acuity ( BCVA ) use ETDRS chart iv ) Safety parameter - Systemic adverse event ( MI , CVA , etc ) - Ocular adverse event ( retinal detachment , RPE tear , endophthalmitis , uveitis , vitreous hemorrhage , subretinal hemorrhage , cataract , IOP elevation , etc ) Methodology : single center , prospective , interventional , one arm , pilot study Evaluation Participants evaluate full ocular examination visit ( VA measurement , tonometry , slit lamp exam ) . Fluorescein angiography ( FA ) perform baseline , 3 month baseline last visit ( 6 month baseline ) , OCT perform monthly ( baseline 1 , 2 , 3 , 4 , 5 , 6 month baseline ) . The microvascular change ( microaneurysm , non-perfusion area , cotton wool spot &amp; hard exudate ) analyze site 1,2 3 field ETDRS ( Fundus Photograph ) FAG ( fluorescein angiography ) &amp; fundus photo baseline 3 month 6 month . And microaneurysm change analyze use Automated RetmarkerDR software ( Critical Health SA ) increase accuracy result . Result analysis The investigator compare difference baseline , 3 month , 6 month . Statistical analysis perform use SPSS ver.12.0 ( SPSS Inc. , Chicago , Il , USA ) . The Wilcoxon sign rank test examine timely change microvascular change ( microaneurysm , non-perfusion area , cotton wool spot &amp; hard exudate )</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients ( Male &amp; female ) ≥18 year age Type 1 2 DM ( HbA1c 7.5 % ) Best correct visual acuity 30/20 20/200 ( Snellen equivalent use ETDRS chart ) Mild moderate NPDR DME Classification diabetic retinopathy ETDRS Mild NPDR At least one microaneurysm , AND criterion meet severe retinopathy Moderate NPDR Hemorrhage/microaneury ≥ standard photograph 2A ; and/or cotton wool spot , venous beading , IRMA definitely present ; criterion meet severe retinopathy Severe NPDR Cotton wool spot , venous beading , IRMA definitely present least two photographic field 4 7 ; two three precede feature present least two field 4 7 hemorrhages/microaneurysm present field 4 7≥ standard photograph 2A least one ; IRMA present field 4 7 ≥ standard photography 8A least two ; criterion meet severe retinopathy PDR NVE &amp; NVD Early PDR New vessel ; criterion meet highrisk PDR High risk PDR New vessel within one disc diameter optic disc ( neovascularization disc ) ≥ standard photograph 10A without vitreous preretinal hemorrhage ; vitreous and/or preretinal hemorrhage accompany new vessel , either NVD ≤ standard photograph 10A new vessel elsewhere ( NVE ) ≥ 1/4 disc area Vitreous hemorrhage Prior intraocular operation history . Pars Plana Vitrectomy , RD surgery , recent ( 4 month ) cataract Op , et al Prior intravitreal injection history . Lucentis , Eylea , Macugen , Avastin , Triamcinolone et al Prior pan retinal photocoagulation ( PRP ) sector scatter photocoagulation do . Uncontrolled hypertension . Uncontrolled glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>